Lipid profile among girls with systemic lupus erythematosus

Machado, Daniele G.; Sarni, Roseli Saccardo; Abad, Thais Tobaruela Ortiz; Silva, Simone G. L.; Khazaal, Eugênia J. B.; Hix, Sonia; Correia, Milena; Souza, Fabíola Isabel Suano de; Len, Cláudio Arnaldo; Terreri, Maria Teresa

doi:10.1007/s00296-015-3393-z

Cited by 23 publications

(15 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our group has previously reported a high prevalence of dyslipidemia in children and adolescents with JIA and jSLE. [6][7][8][9] It is well established in the literature that dyslipidemia is a relevant factor for triggering the atherosclerotic process. 1 To our knowledge, this is the first study conducted in the pediatric population that describes the prevalence of dyslipidemia in individuals with JDM.…”

Section: Resultsmentioning

confidence: 99%

Lipid profile of pediatric patients with chronic rheumatic diseases - a retrospective analysis

Rodrigues

Sarni

Abad

et al. 2020

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

SUMMARY AIM To describe the prevalence of dyslipidemia in children and adolescents with autoimmune rheumatic diseases (ARDs), particularly juvenile idiopathic arthritis (JIA), juvenile systemic lupus erythematosus (jSLE), and juvenile dermatomyositis (JDM). METHODS Retrospective cross-sectional study conducted in the pediatric rheumatology outpatient clinic. We evaluated 186 children and adolescents between the ages of 5 and 19 years. The medical records were reviewed for the following data: demographic and clinical features, disease activity, and lipid profile (triglycerides (TG), total cholesterol (TC), low density lipoprotein (LDL-C), high density lipoprotein (HDL-C) and very low density lipoprotein (VLDL-C)). In addition, non-HDL cholesterol was calculated as TC minus HDL-C. The cut-off points proposed by the American Academy of Pediatrics were used to classify the lipid profile. RESULTS Dyslipidemia was observed in 128 patients (68.8%), the most common being decreased HDL-C (74 patients, 39.8%). In the JIA group there was an association between the systemic subtype and altered LDL-C and NHDL-C, which demonstrated a more atherogenic profile in this subtype (p=0.027 and p=0.017, respectively). Among patients with jSLE, the cumulative corticosteroid dose was associated with an increase in LDL-C (p=0.013) and with a decrease in HDL-C (p=0.022). CONCLUSION Dyslipidemia is common in children and adolescents with ARDs, especially JIA, jSLE, and JDM, and the main alteration in the lipid profile of these patients was decreased HDL-C.

show abstract

Section: Resultsmentioning

confidence: 99%

Lipid profile of pediatric patients with chronic rheumatic diseases - a retrospective analysis

Rodrigues

Sarni

Abad

et al. 2020

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

show abstract

“…HDL in SLE also has abnormal proteomic features, with changes in Apo A‐I being the most noteworthy. In the study by Machado et al, female adolescents with SLE had a higher ratio of HDL cholesterol to Apo A‐I compared to healthy controls, indicating that the HDL particles in those SLE patients had a lesser amount of Apo A‐I . Juárez‐Rojas et al reported lower Apo A‐I and higher Apo E content in HDL particles isolated from women with SLE .…”

Section: Changes In Hdl Composition In Sle Patientsmentioning

confidence: 96%

High‐Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy

Kim

Morin

et al. 2019

Arthritis & Rheumatology

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) patients exhibit accelerated development of atherosclerosis and increased incidents of cardiovascular disease (CVD) that cannot be explained by traditional risk factors alone. Accumulating evidence suggests that reduced levels of high‐density lipoproteins (HDLs), along with altered HDL composition and function, may contribute to the accelerated atherosclerosis in SLE patients. Normally, HDLs play various atheroprotective roles through facilitating cholesterol efflux, inhibiting vascular inflammation, and scavenging oxidative species. However, systemic inflammation, oxidative stress, and autoimmunity in SLE patients induce changes in HDL size distribution and proteomic and lipidomic signatures. These compositional changes in HDLs result in the formation of proinflammatory, dysfunctional HDL. These lupus‐altered HDLs have impaired antiatherogenic function with reduced cholesterol efflux capacities, impaired antioxidation abilities, and diminished antiinflammatory properties. In fact, dysfunctional HDL may promote atherogenesis by inducing inflammation. Thus, dysfunctional HDLs could be an important biomarker of accelerated atherosclerosis in lupus. Additionally, HDL‐targeted therapies, especially infusion of reconstituted HDLs, may serve as a potential therapeutic intervention for SLE patients with CVD.

show abstract

“…Reduced ApoA1 and reduced HDL concentration have been reported previously in JSLE patients compared with healthy donors [43] and increased Apo-B was associated with arterial stiffness in adult SLE patients [44].…”

Section: Discussionmentioning

confidence: 55%

Metabolomics in juvenile-onset SLE: identifying new biomarkers to predict cardiovascular risk

Robinson

Waddington

Coelewij

et al. 2019

Preprint

View full text Add to dashboard Cite

BACKGROUND: Juvenile-onset systemic lupus erythematosus (JSLE) is an autoimmune disorder characterised by immune dysregulation, chronic inflammation and increased cardiovascular risk (CVR). Cardiovascular disease is the leading cause of mortality in JSLE patients not attributable to disease flares. However, it is not possible to predict those patients at greatest risk using traditional CVR factors. METHODSerum metabolomic analysis was performed using a nuclear magnetic resonance spectroscopy-platform in 31 JSLE patients. Data was analysed using cluster, linear regression and receiver operating characteristic analysis. Results were validated in a second cohort of 31 JSLE patients and using data from a cohort of adult-onset SLE patients with known pre-clinical atherosclerotic plaque. RESULTS: Unbiased hierarchical clustering of metabolomic data identified three patient groups. Group-1 had decreased atheroprotective high density lipoproteins (HDL) and increased atherogenic very low and low density lipoproteins (VLDL/LDL); Group-2 had elevated HDL but reduced VLDL/LDL; and Group-3 had low HDL/VLDL/LDL levels. Notably, apolipoprotein(Apo)B1:ApoA1 ratio, a known CVR marker in adult cohorts, was elevated in Group-1 JSLE patients compared to Groups-2/3. The metabolomic signature was validated in a second JSLE cohort and compared with lipid biomarkers previously associated with pre-clinical atherosclerotic plaque in adult SLE patients. Linear regression analysis accounting for demographics, treatment, disease activity, lupus serological markers and body mass index confirmed that a unique metabolomic profile could differentiate between JSLE patients at high and low CVR. CONCLUSIONS: Patient stratification using ApoB:ApoA1 ratio and lipoprotein signatures could facilitate tailored lipid modification therapies and/or diet/lifestyle interventions to combat increased CVR in JSLE.

show abstract

Lipid profile among girls with systemic lupus erythematosus

Cited by 23 publications

References 38 publications

Lipid profile of pediatric patients with chronic rheumatic diseases - a retrospective analysis

Lipid profile of pediatric patients with chronic rheumatic diseases - a retrospective analysis

High‐Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy

Metabolomics in juvenile-onset SLE: identifying new biomarkers to predict cardiovascular risk

Contact Info

Product

Resources

About